Vertex Pharmaceuticals Incorporated (VRTX) : Northeast Financial Consultants Inc reduced its stake in Vertex Pharmaceuticals Incorporated by 0.83% during the most recent quarter end. The investment management company now holds a total of 23,192 shares of Vertex Pharmaceuticals Incorporated which is valued at $2,354,684 after selling 193 shares in Vertex Pharmaceuticals Incorporated , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Vertex Pharmaceuticals Incorporated makes up approximately 1.05% of Northeast Financial Consultants Inc’s portfolio.
Other Hedge Funds, Including , Meiji Yasuda Asset Management Co Ltd. added VRTX to its portfolio by purchasing 2,339 company shares during the most recent quarter which is valued at $237,479. Vertex Pharmaceuticals Incorporated makes up approx 0.03% of Meiji Yasuda Asset Management Co Ltd.’s portfolio.Cambridge Investment Research Advisors boosted its stake in VRTX in the latest quarter, The investment management firm added 136 additional shares and now holds a total of 6,688 shares of Vertex Pharmaceuticals Incorporated which is valued at $685,052. Vertex Pharmaceuticals Incorporated makes up approx 0.01% of Cambridge Investment Research Advisors’s portfolio.Jennison Associates boosted its stake in VRTX in the latest quarter, The investment management firm added 1,920,658 additional shares and now holds a total of 2,974,800 shares of Vertex Pharmaceuticals Incorporated which is valued at $298,788,912. Vertex Pharmaceuticals Incorporated makes up approx 0.31% of Jennison Associates’s portfolio.
Vertex Pharmaceuticals Incorporated closed down -0.15 points or -0.15% at $96.94 with 5,95,225 shares getting traded on Monday. Post opening the session at $97.48, the shares hit an intraday low of $95.57 and an intraday high of $97.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Aug 16, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $108 .
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.